Scientific Reference

Cagrilintide + Semaglutide

Evidence profile: Component evidence only — this formulation has not itself been studied

This combination pairs GLP-1 receptor activation with amylin signalling, representing a dual-pathway metabolic research protocol.\n\nSemaglutide targets GLP-1 pathways, while Cagrilintide acts on amylin receptors. No clinical trials have evaluated this exact combination.

Published Research

REDEFINE 1
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
Garvey WT et al. · The New England journal of medicine · 2025 · Clinical · Evidence for Cagrilintide
PMID 40544433 — View on PubMed
SELECT
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff AM et al. · The New England journal of medicine · 2023 · Clinical · Evidence for Semaglutide
PMID 37952131 — View on PubMed
Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial
Lau DCW et al. · Lancet (London, England) · 2021 · Clinical · Evidence for Cagrilintide
PMID 34798060 — View on PubMed
STEP 1
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding JPH et al. · The New England journal of medicine · 2021 · Clinical · Evidence for Semaglutide
PMID 33567185 — View on PubMed
Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial
Yamauchi T et al. · The lancet. Diabetes & endocrinology · 2026 · Clinical · Evidence for Cagrilintide
PMID 42009015 — View on PubMed
Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study
Rosenstock J et al. · Lancet (London, England) · 2026 · Clinical · Evidence for Cagrilintide
PMID 42251856 — View on PubMed